RYTM - Rhythm Pharmaceuticals Presents New Data at ESPE 2023 | Benzinga
BOSTON, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today announced four oral presentations at the 61st Annual European Society for Paediatric Endocrinology (ESPE) Meeting being held September 21-23, 2023 in The Hague, Netherlands.
"We are excited to deliver multiple presentations at ESPE 2023 including statistics that deepen the understanding of the genetics of obesity from our Rare Obesity Advanced Diagnosis™ (ROAD) testing program as we learn more about the importance of genetics in patients with early-onset, severe obesity," said David Meeker, M.D., Chair, President and Chief Executive Officer of Rhythm.
Impact of Setmelanotide on Metabolic Syndrome Risk
Andrea Haqq, M.D., Division of Pediatric Endocrinology, University of Alberta in Canada, and Jesús Argente M.D., Ph.D., Department of Pediatrics and Pediatric Endocrinology, Universidad Autónoma de Madrid in Spain, delivered an oral presentation on the effects of setmelanotide on the metabolic syndrome severity score based on body mass index (MetS-Z-BMI) score in pediatric patients with Bardet-Biedl syndrome (BBS).
In an oral presentation titled, "Impact of Setmelanotide on Metabolic Syndrome Risk in Pediatric Patients with POMC and LEPR Deficiency," researchers led by Martin Wabitsch, M.D., Ph.D., Department of Pediatrics and Adolescent Medicine, University of Ulm in Germany, presented new findings regarding setmelanotide treatment in pediatric patients with pro-opiomelanocortin (POMC) or leptin receptor (LEPR) deficiency.
Analyses from ROAD genetic testing program
In an oral presentation titled, "Frequency of MC4R Pathway Variants in a European Cohort of Individuals with Early-Onset Severe Obesity," researchers led by Anthony Goldstone, M.D., Ph.D., ...